93
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Inferring transcriptional and microRNA-mediated regulatory programs in glioblastoma

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          • The proneural and mesenchymal transcriptomic subtypes of glioblastoma are associated with distinct regulatory programs.

          • REST, miR-124 and miR-132 are potential drivers of expression changes in proneural glioblastoma, and the inferred extent of dysregulation of miR-132 correlates with survival in the proneural subtype.

          • The expression changes in proneural glioblastoma associated with key regulators in the regression model are consistent with in vivo expression changes in mouse PDGF-driven tumors.

          • Transfection of miR-124 and miR-132 in proneural neurospheres induces expression changes that are concordant with proneural tumor-versus-normal expression changes.

          Abstract

          Large-scale cancer genomics projects are profiling hundreds of tumors at multiple molecular layers, including copy number, mRNA and miRNA expression, but the mechanistic relationships between these layers are often excluded from computational models. We developed a supervised learning framework for integrating molecular profiles with regulatory sequence information to reveal regulatory programs in cancer, including miRNA-mediated regulation. We applied our approach to 320 glioblastoma profiles and identified key miRNAs and transcription factors as common or subtype-specific drivers of expression changes. We confirmed that predicted gene expression signatures for proneural subtype regulators were consistent with in vivo expression changes in a PDGF-driven mouse model. We tested two predicted proneural drivers, miR-124 and miR-132, both underexpressed in proneural tumors, by overexpression in neurospheres and observed a partial reversal of corresponding tumor expression changes. Computationally dissecting the role of miRNAs in cancer may ultimately lead to small RNA therapeutics tailored to subtype or individual.

          Related collections

          Most cited references40

          • Record: found
          • Abstract: found
          • Article: not found

          Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.

          Previously undescribed prognostic subclasses of high-grade astrocytoma are identified and discovered to resemble stages in neurogenesis. One tumor class displaying neuronal lineage markers shows longer survival, while two tumor classes enriched for neural stem cell markers display equally short survival. Poor prognosis subclasses exhibit markers either of proliferation or of angiogenesis and mesenchyme. Upon recurrence, tumors frequently shift toward the mesenchymal subclass. Chromosomal locations of genes distinguishing tumor subclass parallel DNA copy number differences between subclasses. Functional relevance of tumor subtype molecular signatures is suggested by the ability of cell line signatures to predict neurosphere growth. A robust two-gene prognostic model utilizing PTEN and DLL3 expression suggests that Akt and Notch signaling are hallmarks of poor prognosis versus better prognosis gliomas, respectively.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites

            mirSVR is a new machine learning method for ranking microRNA target sites by a down-regulation score. The algorithm trains a regression model on sequence and contextual features extracted from miRanda-predicted target sites. In a large-scale evaluation, miRanda-mirSVR is competitive with other target prediction methods in identifying target genes and predicting the extent of their downregulation at the mRNA or protein levels. Importantly, the method identifies a significant number of experimentally determined non-canonical and non-conserved sites.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              ChIP-seq accurately predicts tissue-specific activity of enhancers.

              A major yet unresolved quest in decoding the human genome is the identification of the regulatory sequences that control the spatial and temporal expression of genes. Distant-acting transcriptional enhancers are particularly challenging to uncover because they are scattered among the vast non-coding portion of the genome. Evolutionary sequence constraint can facilitate the discovery of enhancers, but fails to predict when and where they are active in vivo. Here we present the results of chromatin immunoprecipitation with the enhancer-associated protein p300 followed by massively parallel sequencing, and map several thousand in vivo binding sites of p300 in mouse embryonic forebrain, midbrain and limb tissue. We tested 86 of these sequences in a transgenic mouse assay, which in nearly all cases demonstrated reproducible enhancer activity in the tissues that were predicted by p300 binding. Our results indicate that in vivo mapping of p300 binding is a highly accurate means for identifying enhancers and their associated activities, and suggest that such data sets will be useful to study the role of tissue-specific enhancers in human biology and disease on a genome-wide scale.
                Bookmark

                Author and article information

                Journal
                Mol Syst Biol
                Mol. Syst. Biol
                Molecular Systems Biology
                Nature Publishing Group
                1744-4292
                2012
                28 August 2012
                28 August 2012
                : 8
                : 605
                Affiliations
                [1 ]Computational Biology Program, Memorial Sloan-Kettering Cancer Center , New York, NY, USA
                [2 ]Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center , New York, NY, USA
                [3 ]Department of Pathology, Memorial Sloan-Kettering Cancer Center , New York, NY, USA
                Author notes
                [a ]Computational Biology Program, Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Institute , 1275 York Avenue, New York, NY 10065, USA. Tel.: +1 646 888 2762; Fax: +1 646 422 0717; cleslie@ 123456cbio.mskcc.org
                Article
                msb201237
                10.1038/msb.2012.37
                3435504
                22929615
                03bca7ad-b239-4f71-9645-5c36d33946c1
                Copyright © 2012, EMBO and Macmillan Publishers Limited

                This is an open-access article distributed under the terms of the Creative Commons Attribution Noncommercial No Derivative Works 3.0 Unported License, which permits distribution and reproduction in any medium, provided the original author and source are credited. This license does not permit commercial exploitation or the creation of derivative works without specific permission.

                History
                : 26 October 2011
                : 25 July 2012
                Categories
                Article

                Quantitative & Systems biology
                micrornas in glioblastoma,microrna regulation,integrative cancer genomics,gene regulatory programs

                Comments

                Comment on this article